Benzinga•2026-04-20
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $32TXG — 10X Genomics Inc
NASDAQ · Life Sciences Tools & Services · Life Sciences Tools & Services
$22.97+31.03%Market cap2.67B
- Latest Close
- $22.97
- 30-Day Move
- +31.0%
- Market Cap
- $2.7B
- Shares Outstanding
- 127,750,000
- P/B Ratio
- 2.59
- ROE
- -5.5%
Analyst consensus: Buy · 22 analysts
NASDAQ:TXGLife Sciences Tools & Services / Life Sciences Tools & ServicesDelayed public snapshot
10X Genomics Inc
A read-only Alphactor snapshot for10X Genomics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$22.97
30-Day Move
+31.0%
Market Cap
$2.7B
Shares Outstanding
127,750,000
P/B Ratio
2.59
ROE
-5.5%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$22.97
+31.0%last 90 delayed daily bars
Market cap$2.7B
90D High
$26.45
90D Low
$15.18
Avg Volume
2,484,732
What stands out
Gross margin is running at 69.1%, which gives a quick read on operating quality before you open the full model.
Net margin is -6.8%, useful for comparing TXG against peers in Life Sciences Tools & Services.
TXG is up 31.0% over the last 30 trading days shown on this page.
Latest operating income is $-20M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$25.04
Rule of 40
25.5%
Fundamentals snapshot
Latest Close
$22.97
30-Day Move
+31.0%
Market Cap
$2.7B
Shares Outstanding
127,750,000
P/B Ratio
2.59
ROE
-5.5%
ROA
-4.2%
Gross Margin
69.1%
Operating Margin
-9.5%
Net Margin
-6.8%
Debt / Equity
0
Current Ratio
4.46
Latest Revenue
$166M
Financial statement snapshot
Revenue
$166M
Gross Profit
$113M
Operating Income
$-20M
Net Income
$-16M
Gross Margin
6913.0%
Net Margin
-677.0%
Current Ratio
4.46
Debt / Equity
0.00
Valuation snapshot
Fair Value
$25.04
Upside / Downside
+9.0%
Signal
Fairly Valued
Implied Growth
4.5%
DCF
$21.86
EV/Rev
$28.21
Growth Assumption
7.6%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$130M
Valuation spread
Current Price
$22.97
Composite Fair Value
$25.04
DCF
$21.86
EV/Rev
$28.21
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
5.39
Safe
Piotroski
5
Moderate (4-6)
Cash Conversion
-3.12x
Rule of 40
25.5%
Acceptable
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $516M | $-168M | $-166M | $-165M |
| 2023-12-31 | $619M | $-204M | $-255M | $-65M |
| 2024-12-31 | $611M | $-195M | $-183M | $-7M |
| 2025-12-31 | $643M | $-111M | $-44M | $130M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-20
B of A Securities Maintains Neutral on 10x Genomics, Raises Price Target to $30Benzinga•2026-04-20
Reported Earlier, 10x Genomics Announced Atera, A New In Situ Spatial Biology Platform Engineered To Deliver Whole-transcriptome Spatial Analysis With Single-cell Sensitivity At Unprecedented ScaleFinnhub•2026-04-18
10x Genomics : Introduces AteraFinnhub•2026-04-18
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and UnderstoodAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 7,285,580 | 0.06% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3,460,975 | 0.03% | 2025-12-31 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 3,146,950 | 0.03% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 2,681,908 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2,514,642 | 0.02% | 2025-12-31 |
| Fidelity Select PORT.s-Select Medical Technology and Devices PORT. | 1,967,372 | 0.02% | 2026-02-28 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1,600,000 | 0.01% | 2026-02-28 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1,558,575 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$225M
--
Vanguard Group
Filed 2026-01-29
$212M
-1.9%
ARK Investment Management
Filed 2026-02-11
$207M
--
FMR LLC (Fidelity)
Filed 2026-02-17
$194M
+40.9%
Goldman Sachs
Filed 2026-02-10
$50M
+15.4%
Geode Capital Management
Filed 2026-02-09
$46M
+2.9%
Analyst consensus?
Rating(?)
3.64
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
22
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.